PMab-213: A Monoclonal Antibody for Immunohistochemical Analysis Against Pig Podoplanin.

PMab-213: A Monoclonal Antibody for Immunohistochemical Analysis Against Pig Podoplanin. Monoclon Antib Immunodiagn Immunother. 2019 Feb;38(1):18-24 Authors: Kato Y, Yamada S, Furusawa Y, Itai S, Nakamura T, Yanaka M, Sano M, Harada H, Fukui M, Kaneko MK Abstract Podoplanin (PDPN) is known to be expressed in normal tissues, including lymphatic endothelial cells, renal podocytes, and type I lung alveolar cells. Monoclonal antibodies (mAbs) against human, mouse, rat, rabbit, dog, cat, and bovine PDPN have already been established; however, mAbs against pig PDPN (pPDPN) are lacking. In the present study, mice were immunized with pPDPN-overexpressing Chinese hamster ovary (CHO)-K1 cells (CHO/pPDPN), and hybridomas producing mAbs against pPDPN were identified by flow cytometric screening. One of the mAbs, PMab-213 (IgG2b, kappa), could specifically detect CHO/pPDPN cells through flow cytometry and detect pPDPN through western blot analysis. KD of PMab-213 for CHO/pPDPN was determined to be 2.1 × 10-9 M, indicating a high affinity for CHO/pPDPN. Furthermore, PMab-213 strongly stained lymphatic endothelial cells, renal podocytes, and type I lung alveolar cells through immunohistochemistry. PMab-213 is expected to be useful in investigating the function of pPDPN. PMID: 30802179 [PubMed - in process]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

Authors: von Dücker L, Hüning S, Kähler K, Terheyden P, Nashan DRT Abstract In the context of supportive therapy, possible complaints which may be caused by the cancer itself, by the antitumoral therapy or by psychosocial concerns are considered. Due to the introduction of new anticancer drugs in dermato-oncology, clinicians are confronted with a novel spectrum of adverse events. There are a number of inflammatory, immune-mediated side effects caused by immunotherapies, which can affect virtually any organ. Targeted therapies also have specific side effects. Basically, the management of adv...
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
Targeting CD8+ T cells to recurrent tumor-specific mutations can profoundly contribute to cancer treatment. Some of these mutations are potential tumor antigens although they can be displayed by non-spliced epitopes only in a few patients, because of the low affinity of the mutated non-spliced peptides for the predominant HLA class I alleles. Here, we describe a pipeline that uses the large sequence variety of proteasome-generated spliced peptides and identifies spliced epitope candidates, which carry the mutations and bind the predominant HLA-I alleles with high affinity. They could be used in adoptive T cell therapy and ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Condition:   Peanut Allergy Interventions:   Drug: INP20;   Drug: Placebo Sponsors:   InnoUp Farma S.L.;   Syntax for Science, S.L Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Non-Small Cell Lung Cancer Metastatic Interventions:   Drug: Durvalumab;   Drug: Pemetrexed;   Drug: Carboplatin Sponsors:   University of Utah;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Renal Cell Carcinoma Intervention:   Drug: Fecal Microbiota Transplantation Sponsors:   Lawson Health Research Institute;   Academic Medical Organization of Southwestern Ontario Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Advanced Liver Cancer Interventions:   Drug: PD-1;   Drug: Sorafenib Sponsor:   Guangxi Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 14 November 2019Source: Seminars in Cancer BiologyAuthor(s): Radhakrishnan Vishnubalaji, Shaath Hibah, Ramesh Elango, Nehad M. AlajezAbstractSubstantial evolution in cancer therapy has been witnessed lately, steering mainly towards immunotherapeutic approaches, replacing or in combination with classical therapies. Whereas the use of various immunotherapy approaches, such as adoptive T cell therapy, genetically-modified T cells, or immune checkpoint inhibitors, has been a triumph for cancer immunotherapy, the great challenge is the ability of the immune system to sustain long lasting anti-...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 November 2019Source: Nano TodayAuthor(s): Xiaochen Liu, Dangge Wang, Pengcheng Zhang, Yaping LiAbstractCheckpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nano...
Source: Nano Today - Category: Nanotechnology Source Type: research
(University of Texas M. D. Anderson Cancer Center) Prostate cancer that spreads to the bone triggers the destruction of bone tissue that thwarts the effectiveness of immune checkpoint inhibitors. Research points to anti-CTLA-4 and anti-TGF-B combination to protect T cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Cell Press) During spaceflight, astronauts experience similar physical stress as cancer patients undergoing treatments such as chemotherapy, immunotherapy, and targeted therapy. In a commentary published Nov. 14 in the journal Cell, researchers suggest that by mimicking a NASA astronaut's schedule of exercising before, during, and after a mission, cancer patients could reduce the long-term impact their treatments often have on their bodies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: China Health | Immunotherapy | Microbiology | Ovaries | Study